



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 30-12-2010

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL
DESIGNS FOR THE WEEK-ENDING OF 18-12-2010 TO BE
PUBLISHED 03-01-2011 IN THE GAZETTE OF PAKISTAN PART-
V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

Sd/-
(Sabir Gul)
Controller of Patents
& Registrar of Designs
Ph: 99215056

ENCL: Eleven pages.

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

13-12-2010

- | | | |
|-----------|---|---|
| 1032/2010 | Unilever Plc.,
United Kingdom
(Priority 07-01-2010 Europe) | “Natural shading agents” |
| 1033/2010 | Bayer Schering Pharma
Aktiengesellschaft,
Germany
(Priority 22-12-2009 Europe) | “Pyridinone derivatives and
pharmaceutical compositions thereof” |
| 1034/2010 | Abbott Laboratories,
USA
(Priority 16-12-2009 USA) | “Prodrug compounds useful as
cannabinoid ligands” |

14-12-2010

- | | | |
|-----------|---|--|
| 1035/2010 | Bayer CropScience AG.,
Germany
(Priority 28-12-2009 Japan) | “Pesticidal arylpyrrolidines” |
| 1036/2010 | Merck Sharp & Dohme Corp.,
USA
(Priority 17-12-2009 USA) | “Quinoline amide m1 receptor positive
allosteric modulators” |
| 1037/2010 | Maschinenfabrik Rieter AG.,
Switzerland
(Priority 15-12-2009 Germany) | “Ring spindle arrangement comprising a
false twisting device” |
| 1038/2010 | Merck Frosst Canada Ltd.,
Canada
Merck Sharp & Dohme Corp.,
USA
(Priority 17-12-2009 USA) | “Aminopyrimidines as syk inhibitors” |
| 1039/2010 | Abbott Laboratories,
USA
Abbott GmbH, and Co. KG.,
Germany
(Priority 22-12-2009 USA) | “Carboxamide Compounds and their use
as Calpain Inhibitors V” |

1040/2010	H. Lundbeck A/S., Denmark (Priority 15-12-2009 Denmark)	“Pyridone derivatives as NK3 antagonists”
1041/2010	H. Lundbeck A/S., Denmark (Priority 17-12-2009 Denmark)	“2-arylimidazole derivatives as PDE10A enzyme inhibitors”
1042/2010	H. Lundbeck A/S., Denmark (Priority 17-12-2009 Denmark)	“Heteroaromatic aryl triazole derivatives as PDE10A enzyme inhibitors”
1043/2010	H. Lundbeck A/S., Denmark (Priority 17-12-2009 Denmark)	“Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors”
1044/2010	H. Lundbeck A/S., Denmark (Priority 17-12-2009 Denmark)	“Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors”
1045/2010	Boehringer Ingelheim International GmbH., Germany (Priority 17-12-2009 Europe)	“New ccr2 receptor antagonists and uses thereof”
1046/2010	Star Syringe Limited, Great Britain (Priority 16-12-2009 Great Britain)	“Syringes”
1047/2010	Syngenta Limited, United Kingdom (Priority 17-12-2009 United Kingdom)	“Herbicidal compositions comprising, and methods of use of, herbicidally active pyrandiones”
1048/2010	Syngenta Limited, United Kingdom (Priority 17-12-2009 United Kingdom)	“Herbicidal composition comprising a pyrandione herbicide and a co-herbicide”

15-12-2010

1049/2010	Sanofi-Aventis, France (Priority 18-12-2009 Europe)	“Novel antagonist antibodies and their fab fragments against gpvi and uses thereof”
-----------	---	---

1050/2010 Novartis AG., “Organic compositions to treat hsf1-related
Switzerland diseases”
(Priority 18-12-2009 USA)

18-12-2010

1051/2010 Abhay Coatex Private Limited, “An improved process for Cotton Oil
India Miscella Refining”
(Priority 31-08-2010 India)

1052/2010 Gilead Sciences, Inc., “Method of treating atrial fibrillation”
USA
(Priority 21-12-2009 USA)

1053/2010 Vestergaard SA., “Hollow fibre liquid filter”
Switzerland
(Priority 18-12-2009 Denmark)

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


1054/1999 Novartis AG.,
 Switzerland

“An n-(substituted glycy)-2-
 cyanopyrrolidine compound”

CO7D 209/18

141042

The present invention relates to a compound of formula (I)



wherein R is substituted adamantyl; and n is 0 to 3; in free form or in acid addition salt form. Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceutical in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.


743/2003 Aventis Pharma S.A.,
France

“An aminoindazole compound”

CO7D 231/56

141043

The present invention relates to a compound of formula (I)



in which

R3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO₂R1, C(=NH)R1 or C(=NH)NR1 radical;

R5 and R6 are, independently of one another, chosen from the following radicals: halogen, CN, NO₂, NH₂, OH, COOH, C(O)OR8, -O-C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO₂R8, NHSO₂R8, SO₂NR8R9, -O-SO₂R8, -SO₂-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl.

1043/2005 Boehringer Ingelheim
International GmbH.,
Germany

“Process for the preparation of chiral 8-(3-amino-piperidin-1-yl)-xanthine”

A61K 31/522, 31/19, CO7D 473/10, 473/00

141044

The invention relates to an improved process for preparing enantiomerically pure

757/2006 Novartis AG.,
Switzerland


8-(3-aminopiperidin-1-yl)-xanthine.

"A salt of n-(substituted glycy)-2-cyanopyrrolidine"

CO7D 209/18

141045

The present invention relates to a pharmaceutically acceptable acid addition salt of the compound of formula (I)



wherein R is substituted adamantyl; and n is 0 to 3. Salts of the compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceutical in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.


1582/2006 Aventis Pharma S.A.,
France

"A pharmaceutically acceptable salt of aminoindazole compound"

CO7D 231/56

141046

The present invention relates to a racemate, enantiomer, diastereoisomer or a mixture thereof, or a tautomer or a pharmaceutically acceptable salt of a compound of formula (I):



in which

R3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO₂R1, C(=NH)R1 or C(=NH)NR1 radical;

R5 and R6 are, independently of one another, chosen from the following radicals: halogen, CN, NO₂, NH₂, OH, COOH, C(O)OR8, -O-C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO₂R8, NHSO₂R8, SO₂NR8R9, -O-SO₂R8, -SO₂-O-R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl.

1247/2008 Bayer Cropscience AG.,
Germany


“Herbicide composition comprising 2-iodo-N-[4-methoxy-6-methyl-1,3,5-triazin-2-yl] carbamoyl] benzenesulfonamide”

AO1N 43/00

141047

The present invention relates to a herbicide combination comprising components (A) and (B), where

(A) is one or more herbicides from the group consisting of 2-iodo-N-[4-methoxy-6-methyl-1,3,5-triazin-2-yl]carbamoyl]benzenesulfonamide and compounds of the general formula (I)



where

the cation (M⁺) is (a) an alkali metal ion, preferably lithium, sodium, potassium, or

(b) an alkaline earth metal ion, preferably calcium or magnesium, or

(c) a transition metal ion, preferably manganese, copper, zinc or iron, or

(d) an ammonium ion where optionally one, two or three or all four hydrogen atoms are substituted by identical or different radicals from the group consisting of (C₁-C₄)-alkyl, hydroxy-(C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl, (C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, hydroxy-(C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, (C₁-C₆)-mercaptoalkyl, phenyl and benzyl,

where the radicals mentioned above are optionally substituted by one or more identical or different radicals from the group consisting of halogen, such as F, Cl, Br or I, nitro, cyano, azido, (C₁-C₆)-alkyl, (C₁-C₆)-haloalkyl, (C₃-C₆)-cycloalkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-haloalkoxy and phenyl and where in each case two substituents at the nitrogen atom together optionally form an unsubstituted or substituted ring, or

(e) a phosphonium ion, or

(f) a sulfonium ion, preferably tri((C₁-C₄)-alkyl)sulfonium, or

(g) an oxonium ion, preferably tri((C₁-C₄)-alkyl)oxonium, or

(h) a saturated or unsaturated/aromatic nitrogenous heterocyclic ionic compound which has 1-10 carbon atoms in the ring system and is optionally mono- or polycondensed and/or substituted by (C₁-C₄)-alkyl, and

(B) is one or more herbicides from the group of the (het)arylcarboxylic acids

comprising:
dicamba; 2,3,6-TBA; clopyralid;
fluroxypyr; inabenfide; picloram; triclopyr;
quinclorac; quinmerac; indo1-3-ylacetic
acid; 4-indo1-3- ylbutyric acid; 2-(1-
naphthyl)acetamide; 1-naphthylacetic acid;
2- naphthyloxyacetic acid; and
aminocyclopyrachlor.


301/2010 Boehringer Ingelheim
International GmbH.,
Germany

“8-(3-amino-piperidin-1-yl)-xanthines
compound and pharmaceutical composition
comprising thereof:

CO7D 413/64, A61K 31/522

141048

The invention relates a compound of
general formula (I)



or an enantiomer or salt thereof
in which R¹ is a phenylcarbonylmethyl,
benzyl, naphthylmethyl, pyridinylmethyl,
pyrimidinylmethyl, quinolinylmethy,
isoquinolinylmethyl, quinazolinylmethyl,
quinoxalinylmethyl, naphthyridinylmethyl
or phenanthridinylmethyl group in which
the aromatic or heteroaromatic moiety is in
each case mono- or disubstituted by R_a,
where the substituents may be the same or
different and
R_a is a hydrogen, fluorine, chlorine or
bromine atom or a cyano, methyl,
trifluoromethyl, ethyl, phenyl, methoxy,
difluoromethoxy, trifluoromethoxy or
ethoxy group,
or two R_a radicals, when they are bonded to
adjacent carbon atoms, may also be an -O-
CH₂-O- or -O-CH₂-CH₂-O- group,
R² is a methyl, ethyl, propyl, isopropyl,
cyclopropyl or phenyl group and

R^3 is a 2-buten-1-yl, 3-methyl-2-buten-1-yl, 2-butyne-1-yl, 2-fluorobenzyl, 2-chlorobenzyl, 2-bromobenzyl, 2-iodobenzyl, 2-methylbenzyl, 2-(trifluoromethyl) benzyl or 2-cyanobenzyl group, and pharmaceutical composition comprising thereof.

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>13-12-2010</u>			
1)	15091	Filter (Class-)	Unilever PLC
<u>14-12-2010</u>			
2)	15092	Iron Paint Gallon (Class-)	Brighto Paints (Pvt.) Ltd
3)	15093	Plastic Paint Gallon (Class-03)	Brighto Paints (Pvt.) Ltd

Sd/-
(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215056